- This topic has 66 replies, 14 voices, and was last updated 8 years, 3 months ago by
.
-
Thanks Price, that was something I wondered about from the data I’d seen. So this is a great reminder that I had planned to review in more detail rather than just skimming.
I guess the current riba cohort size in the DAA reviews is too small yet to provide any confidence but my AFP has dropped to 4.5 under Tx. Maybe something there?
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
Ariel:
I am a big believer in prevention and maximizing success. The bad thing is that usually nobody listens to me
Re : anxiety and stress
Someone very dear to me treated with interferon three times and ended up with severe stress intolerance and anxiety. He avoids anything that may be stressful. He no longer reads threads that may be upsetting and avoids people that create stress for him. Since I’m an advocate and I’m often involved in drama, I belong in that group.
So I do understand.I’m going after the answers. I’ve been researching the topic for months, Want to hear what I found out so far? Don’t worry, it’s optimistic!
Tomorrow I’ll start a separate thread so I can tell you.
P.
Hi Jeff, hopefully some of the rain from your parade falls into my glass (only just) half full, I could use it.
My understanding is that raised AFP can mean a lot of things but sudden increases are always worth close scrutiny. The drop is apparently probably good too but mostly gives me a low base to watch for increases over the next few months.
When you say “the pointy end” I believe you mean at the forefront of scientific research!
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
We do need to be careful with what we read into this recent report. It is really an advisory of initial findings that may not be totally cohort neutral. Due to the retrospective nature of the study there may have been some selection in favour of those with HCC recurrence which is why additional study has commenced.
Also we should keep in mind something one of the study authors points out:
“This is a different cancer than elsewhere in oncology — it is a cancer within an advanced chronic disease — so the prognosis, the life expectancy, is related not only to the liver cancer but also to the liver disease and liver function,” he explained. “If you don’t treat these patients and ameliorate their liver function, and if hepatocellular carcinoma occurs, you have no chance of curing them. But if you ameliorate liver function and they develop hepatocellular carcinoma, you can cure it better because their improved liver function will allow an ablation.”
So for those with prior HCC who are now treating with DAAs it should act as an advisory to instigate careful and more regular than usual monitoring during the initial period post EOT.
Edit: yes Jeff you are correct about share prices, always look at the authors declarations of interest too.
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
Ty Sabrecat
Good to be vigilant in all areas
No HCC here just other stuff from peginf times. Will keep an eye on it already booked for colonscopy and cytoscopy
Cheers A
- You must be logged in to reply to this topic.